Sun Pharma & Merck & Co. Inc. enter into licensing agreement for Tildrakizumab

Sun Pharma to acquire worldwide tights for Tildrakizumab

Sun Pharmaceutical Industries and Merck & Co. Inc. announced an exclusive worldwide licensing agreement for Merck's investigational therapeutic antibody candidate, Tildrakizumab, (MK-3222), which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment.

Under terms of the agreement, Sun Pharma will acquire worldwide rights to Tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of U.S. $80 million. Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post approval studies, manufacturing and commercialization of the approved product.

Powered by Capital Market - Live News